News for Actinogen Medical Limited (ACW.AX)

The search for an effective treatment for neurological conditions like Alzheimer’s disease…

Actinogen's Xanamem has been granted a medical, non-proprietary name, ‘emestedastat’, by the World Health Organization. This a big deal.

Actinogen Medical Ltd said it had pared back net losses in the 6 months to December 2024, a development activity increased

PR NewswireSYDNEY, Feb. 12, 2025 Confirms the utility of the 10 mg daily oral dose of Xanamem being studied in late-stage clinical trials in Alzheimer's di

PR NewswireSYDNEY, Dec. 9, 2024 Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026 Appoints US-based Chief Commercial

Gold rose after China’s central bank added bullion to its reserves in November, resuming a key pillar of support for the precious metal. Bullion climbed by 0.5% to US$2,640.

Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s.

Actinogen Medical Ltd has received a $9M R&D rebate from the Australian Taxation Office which will fund its activities through to mid-2026

Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.

Durable benefits previously reported for the MADRS depression scale are supported by the patient-reported outcome of PGI-S and new MADRS responder analyses that underscore benefit at week 10 with a 50% higher rate of remission of depression

Australian biotechnology company Actinogen Medical (ASX: ACW) has received further positive analysis from studies of its Xanamem treatment for symptoms of

Actinogen Medical (ASX:ACW) recently announced results from its XanaCIDD Phase 2a trials, which demonstrated the drug's significant clinical and statistical benefits over a placebo in treating depression.

There was a clinically meaningful and persistent improvement depression measured by the key secondary endpoint of MADRS.[1] The primary endpoint of superiority to placebo in a cognitive 'attention composite' of three Cogstate computerized tests was not met with large improvements seen in both Xanamem and placebo groups. Xanamem was safe and well tolerated.

Aussie markets have somehow pulled of a miracle gain despite two horror sessions this week.

Enrolment completed in Actinogen's XanaCIDD phase 2a cognition & depression trial

/PRNewswire/ -- XanaMIA Phase 2b trial...

There were 191 ASX IPOs in calendar year 2021, and 15 of them were biotech stocks.But in 2022 there were only 3 biotech listings.

Five excellent reasons why fossil fuel subsidies suck, David Southam chats about his pivot to lithium, and why OPEC got it wrong.

The benchmark inched up for the day, little miners kicked some goals and Star's in big trouble... just wait until dad gets home.